×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Animal Vaccines Market Analysis

ID: MRFR/HC/5718-CR
200 Pages
Rahul Gotadki
July 2025

Animal Vaccines Market Research Report: Size, Share, Trend Analysis By Technology (Inactivated Vaccines, Attenuated Vaccines, Subunit Vaccines, DNA Vaccines, mRNA Vaccines), By Animal Type (Pets, Livestock, Poultry, Wildlife, Aquaculture), By Route of Administration (Injectable, Oral, Intranasal, Topical), By Distribution Channel (Veterinary Clinics, Retail Pharmacies, Online Pharmacies, Animal Hospitals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Animal Vaccines Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Analysis

In-depth Analysis of Animal Vaccines Market Industry Landscape

The animal vaccines market is an essential part of veterinary medication, adding to the health and prosperity of different species. It includes the development, creation, and dispersion of vaccines to forestall or relieve irresistible sicknesses in animals, going from pets to animals. The market elements are unequivocally impacted by the preventive healthcare approach, where vaccination assumes a vital part in controlling the spread of sicknesses among animals. As mindfulness develops with respect to the advantages of vaccination in averting ailments, the demand for animal vaccines keeps on rising. The expanding pet proprietorship pattern contributes altogether to the market elements. As additional families invite pets as a component of the family, there is a comparing expansion in the demand for vaccines to guarantee the health and life span of companion animals. The domesticated animals area's significance in giving a steady food supply impacts the elements of the animal vaccines market. Vaccination programs are basic for maintaining the health of crowds and runs, forestalling the spread of sicknesses that could affect food creation and supply chains. Zoonotic illnesses, those that can be sent from animals to people, gather consideration in the market elements. The attention to potential health dangers from animals highlights the significance of complete vaccination methodologies to safeguard both animal and human populations. The capacity to screen and answer illness flare-ups is pivotal in the animal vaccines market. Epidemiological observation illuminates vaccination techniques, and fast reaction capacities become fundamental in controlling the spread of irresistible sicknesses among animals. The market is portrayed by rivalry among central participants in the veterinary drug industry. Consolidations, acquisitions, and coordinated efforts are normal procedures as organizations look to expand their item portfolios and improve their market presence. The variety of animal species, each with extraordinary health needs, drives the market elements toward the development of specific vaccines. From companion animals like canines and felines to enormous animals, vaccines are tailored to address explicit health challenges inside every species.

Author
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Animal Vaccines Market as of 2024?

<p>The Animal Vaccines Market was valued at 11.52 USD Billion in 2024.</p>

What is the projected market size for the Animal Vaccines Market by 2035?

<p>The market is projected to reach 25.83 USD Billion by 2035.</p>

What is the expected CAGR for the Animal Vaccines Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Animal Vaccines Market during 2025 - 2035 is 7.62%.</p>

Which companies are considered key players in the Animal Vaccines Market?

<p>Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, and Virbac.</p>

How does the market segment for Preventive Vaccination perform in terms of valuation?

<p>The Preventive Vaccination segment is projected to grow from 4.5 USD Billion to 10.2 USD Billion.</p>

What is the valuation range for the Therapeutic Vaccination segment?

<p>The Therapeutic Vaccination segment ranges from 3.0 USD Billion to 7.0 USD Billion.</p>

What are the projected values for the Livestock segment by 2035?

<p>The Livestock segment is expected to grow from 5.0 USD Billion to 11.5 USD Billion.</p>

What is the expected growth for the Companion Animals segment in the Animal Vaccines Market?

<p>The Companion Animals segment is projected to increase from 3.0 USD Billion to 7.0 USD Billion.</p>

Which route of administration shows the highest projected growth?

<p>The Intramuscular route of administration is expected to grow from 3.0 USD Billion to 7.0 USD Billion.</p>

What is the projected valuation for Inactivated Vaccines by 2035?

<p>Inactivated Vaccines are projected to grow from 3.45 USD Billion to 7.8 USD Billion by 2035.</p>

Market Summary

As per MRFR analysis, the Animal Vaccines Market Size was estimated at 11.52 USD Billion in 2024. The Animal Vaccines industry is projected to grow from 12.39 USD Billion in 2025 to 25.83 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.62% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Animal Vaccines Market is experiencing robust growth driven by technological advancements and increasing demand for preventive healthcare.

  • Technological advancements in vaccine development are reshaping the Animal Vaccines Market, particularly in North America. The rising demand for preventive healthcare is propelling the growth of the preventive vaccination segment, which remains the largest. Focus on zoonotic disease prevention is gaining traction, especially in the Asia-Pacific region, which is the fastest-growing market. Increasing pet ownership and rising awareness of animal health are key drivers fueling market expansion across both livestock and companion animal segments.

Market Size & Forecast

2024 Market Size 11.52 (USD Billion)
2035 Market Size 25.83 (USD Billion)
CAGR (2025 - 2035) 7.62%
Largest Regional Market Share in 2024 North America

Major Players

Zoetis (US), Merck Animal Health (US), <a href="https://www.boehringer-ingelheim.com/in/animal-health">Boehringer Ingelheim</a> (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR), Phibro Animal Health (US)

Market Trends

The Animal Vaccines Market is currently experiencing a notable transformation, driven by advancements in biotechnology and an increasing awareness of animal health. The demand for effective vaccines is rising, as pet ownership and livestock farming continue to expand globally. This trend is further fueled by the growing emphasis on food safety and the prevention of zoonotic diseases, which underscores the importance of immunization in both companion and agricultural animals. As a result, manufacturers are investing in research and development to create innovative vaccine solutions that cater to diverse species and health challenges. Moreover, regulatory frameworks are evolving to support the introduction of new vaccines, which may enhance market dynamics. The integration of digital technologies in vaccine distribution and monitoring is also gaining traction, potentially improving accessibility and efficiency. Stakeholders in the Animal Vaccines Market are likely to focus on strategic partnerships and collaborations to enhance their product offerings and expand their market reach. Overall, the landscape appears promising, with various factors indicating sustained growth and development in the sector.

Technological Advancements in Vaccine Development

The Animal Vaccines Market is witnessing a surge in technological innovations, particularly in the development of recombinant and DNA vaccines. These advanced formulations may offer enhanced efficacy and safety profiles, addressing the evolving health needs of animals. As research progresses, the potential for more targeted and effective immunization strategies becomes increasingly apparent.

Rising Demand for Preventive Healthcare

There is a growing trend towards preventive healthcare in the Animal Vaccines Market, driven by heightened awareness among pet owners and livestock producers. This shift emphasizes the importance of vaccination as a proactive measure to ensure animal health and productivity, potentially leading to increased market penetration and consumer engagement.

Focus on Zoonotic Disease Prevention

The Animal Vaccines Market is increasingly prioritizing the prevention of zoonotic diseases, which can be transmitted from animals to humans. This focus may lead to the development of vaccines specifically designed to combat these diseases, reflecting a broader commitment to public health and safety.

Animal Vaccines Market Market Drivers

Growing Demand for Animal Protein

The increasing global demand for animal protein is significantly influencing the Global Animal Vaccines Market Industry. As populations grow and dietary preferences shift towards protein-rich foods, the livestock sector faces pressure to enhance productivity and health. Vaccination plays a crucial role in ensuring the health of livestock, thereby improving yield and quality. This demand is expected to drive the market towards a valuation of 10 USD Billion by 2035. Consequently, the emphasis on vaccination as a means to sustain animal health and productivity is likely to remain a key focus for stakeholders in the industry.

Rising Awareness of Animal Health

The growing awareness of animal health and welfare among pet owners and livestock producers is significantly impacting the Global Animal Vaccines Market Industry. As consumers become more informed about the benefits of vaccination, there is a corresponding increase in demand for veterinary services and preventive healthcare measures. This trend is particularly evident in developed regions, where pet ownership is high, and owners are more likely to invest in their pets' health. The heightened focus on animal welfare is likely to drive market growth, as stakeholders recognize the importance of vaccination in promoting healthy and productive animals.

Regulatory Support and Initiatives

Regulatory frameworks and government initiatives aimed at promoting animal health are pivotal drivers of the Global Animal Vaccines Market Industry. Governments worldwide are implementing policies that encourage vaccination programs to prevent disease outbreaks and protect public health. For example, initiatives that subsidize vaccine costs or provide funding for research and development contribute to increased vaccination rates among livestock and pets. This regulatory support is expected to facilitate market growth, as it aligns with global health objectives and enhances the overall effectiveness of vaccination strategies.

Increasing Animal Disease Incidence

The rising incidence of infectious diseases among livestock and companion animals is a primary driver of the Global Animal Vaccines Market Industry. For instance, outbreaks of diseases such as avian influenza and foot-and-mouth disease have prompted governments and veterinary organizations to prioritize vaccination programs. This trend is expected to contribute to the market's growth, with the industry projected to reach 6.21 USD Billion in 2024. The need for effective vaccination strategies to combat these diseases underscores the importance of animal vaccines in maintaining animal health and ensuring food security.

Technological Advancements in Vaccine Development

Technological innovations in vaccine development are reshaping the Global Animal Vaccines Market Industry. Advances in biotechnology, such as recombinant DNA technology and mRNA vaccines, are enhancing the efficacy and safety of animal vaccines. These innovations not only improve vaccine performance but also reduce production costs, making vaccines more accessible to farmers. As a result, the market is poised for growth, with a projected CAGR of 4.43% from 2025 to 2035. The integration of cutting-edge technologies into vaccine development is likely to bolster the industry's capacity to address emerging animal health challenges.

Market Segment Insights

By Application: Preventive Vaccination (Largest) vs. Therapeutic Vaccination (Fastest-Growing)

The Animal Vaccines Market primarily comprises three applications: Preventive, Therapeutic, and Emergency Vaccination. Preventive Vaccination is the largest segment, capturing a significant portion of the market share due to its essential role in safeguarding animal health against diseases. As livestock production intensifies to meet global food demand, the reliance on preventive measures has grown, solidifying its status in the market. On the other hand, Therapeutic Vaccination, while smaller in market share, is emerging as the fastest-growing segment. This growth is primarily driven by advancements in vaccine technology and the increasing focus on disease treatment in animals. The rising awareness and demand for innovative therapeutic options create an evolving landscape, suggesting that this segment will see rapid expansion in the coming years.

Preventive Vaccination (Dominant) vs. Therapeutic Vaccination (Emerging)

Preventive Vaccination stands as the dominant player in the Animal Vaccines Market, primarily focused on immune protection through vaccination before the onset of diseases. This proactive approach is vital for maintaining herd health, reducing disease outbreaks, and enhancing animal productivity. In contrast, Therapeutic Vaccination, while categorized as an emerging segment, caters to specific health challenges faced by animals after disease manifestation. Its development focuses on targeted therapies that enhance recovery and improve health outcomes, reflecting a significant shift toward effective disease management. Both segments play crucial roles; however, preventive measures currently dominate due to their essential protective nature.

By Animal Type: Livestock (Largest) vs. Companion Animals (Fastest-Growing)

The Animal Vaccines Market is primarily segmented into Livestock, Companion Animals, Aquatic Animals, and Wildlife. Livestock holds the largest share, driven by the extensive need for vaccines to prevent diseases in cattle, sheep, and pigs. This segment encompasses a significant proportion of the market, reflecting the importance of maintaining animal health for food production. Companion Animals, while currently a smaller segment, are witnessing significant growth due to the increasing pet ownership and rising awareness of pet health, leading to a higher demand for vaccines. The growth trend for Companion Animals is bolstered by changing consumer attitudes towards pet care, with more pet owners seeking preventative health measures and better veterinary services. Additionally, the rise in disposable income and an increase in veterinarian visits are driving the demand for vaccines targeted at pets. Conversely, the Livestock segment, although dominant, faces pressures such as the need for more innovative solutions to address emerging diseases and comply with regulations, pushing for advancements in vaccine research and development.

Livestock (Dominant) vs. Companion Animals (Emerging)

The Livestock segment is characterized by its strong market position, largely due to the demand for vaccines that protect against prevalent diseases affecting farm animals. This segment relies heavily on established veterinary practices and government regulations that promote animal health standards. With a robust infrastructure in place, Livestock vaccines are developed to cater specifically to large populations of animals, which makes them economically viable for farmers. In contrast, the Companion Animals segment, though smaller in scope, is marked by rapid growth driven by shifting consumer perspectives on pet ownership. As pet owners increasingly treat pets as family members, there is a growing shift towards preventative healthcare, leading to a surge in the development of tailored vaccines and innovative treatment options.

By Route of Administration: Intramuscular (Largest) vs. Oral (Fastest-Growing)

<p>The animal vaccines market is segmented based on the route of administration, with intramuscular and subcutaneous routes holding the largest market shares. Intramuscular administration is preferred for its efficacy and quick immunologic response among various species, especially in larger animals. Subcutaneous administration follows close behind, favored for its ease of use and minimal discomfort. Oral vaccines, while traditionally less favored, are gaining traction due to advancements in formulation technology, enhancing their effectiveness and appealing to livestock and pet owners seeking less invasive methods. Market growth in this segment is driven by increasing awareness of animal health, rising incidences of infectious diseases, and the demand for efficient vaccination strategies. Oral vaccines are becoming an emerging segment as they offer advantages like ease of administration and reduced stress on animals, propelling their growth. Meanwhile, the continued reliance on intramuscular vaccines ensures their dominance in the market, reflecting educators' and veterinarians' preferences.</p>

<p>Administration Route: Intramuscular (Dominant) vs. Oral (Emerging)</p>

<p>The intramuscular route of administration has long been established as the dominant method in the animal vaccines market, primarily due to its effectiveness in eliciting strong immune responses across various animal species. This route is especially popular for large animals where quick vaccination is imperative for protecting against serious diseases. Conversely, the oral administration route is emerging as a viable alternative, particularly within the livestock sector. Its benefits include ease of delivery and reduced stress for the animals, making it an attractive option for farmers and veterinarians. The growing focus on animal wellbeing is driving innovations in oral vaccine formulations, thereby enhancing their acceptance and reliability in preventing infectious diseases.</p>

By Technology: Inactivated Vaccines (Largest) vs. Recombinant Vaccines (Fastest-Growing)

The Animal Vaccines Market technology segment showcases a diverse range of vaccine platforms, with inactivated vaccines holding the largest market share. These vaccines, characterized by their effective immunization against various diseases in animals, are widely adopted by veterinarians and livestock farmers alike. Live attenuated vaccines and DNA vaccines also play significant roles but are eclipsed by the dominance of inactivated vaccines. Recombinant vaccines, however, are gaining traction due to their safety profile and efficiency, indicating a shift in preferences within the market. Growth trends in the Animal Vaccines Market are largely driven by increasing awareness of animal health and the rising demand for sustainable livestock production. The advancement in biotechnology is fostering innovation in the vaccine development landscape, especially for recombinant and DNA vaccines. This surge is supported by regulatory approvals and a focus on novel vaccine delivery systems, which are expected to enhance immunogenicity and reduce side effects. As the industry evolves, we anticipate a sustained shift towards these emerging technologies alongside the existing inactivated vaccines, shaping the market's future landscape.

Technology: Inactivated Vaccines (Dominant) vs. Recombinant Vaccines (Emerging)

Inactivated vaccines, renowned for their reliability and long-standing presence in veterinary medicine, dominate the Animal Vaccines Market. They are specifically developed to trigger strong immune responses without posing risks of disease transmission, making them the preferred choice among animal health professionals. Meanwhile, recombinant vaccines are emerging as a key rival in this segment. Leveraging genetic engineering, these vaccines offer precise and efficient protection against specific pathogens. Their development is boosted by the growing need for safer vaccine options that protect both livestock and companion animals, thus appealing to a broader market. As regulatory frameworks evolve to embrace these innovations, recombinant vaccines are poised to capture significant attention and market share, reshaping the future of animal immunization.

By End User: Veterinary Clinics (Largest) vs. Animal Hospitals (Fastest-Growing)

In the Animal Vaccines Market, veterinary clinics represent the largest segment, driven by their comprehensive services and direct access to pet owners. Following closely, animal hospitals are experiencing accelerated growth, as they offer specialized care and advanced medical services. Research institutions and farmers, though significant, hold a smaller share compared to these two pivotal segments, influenced by varying demand dynamics for vaccines used in research and livestock management. As the market evolves, these establishments play crucial roles in vaccine distribution and administration, contributing significantly to animal health initiatives. Recent trends indicate a rising demand for veterinary services in both urban and rural areas, further propelling the growth of veterinary clinics and animal hospitals. Factors such as increased pet ownership and a greater emphasis on animal health are driving the need for effective vaccines. Additionally, the expansion of research institutions focusing on veterinary sciences is set to bolster innovations, ensuring that the sector adapts to emerging health challenges amongst livestock and companion animals alike.

Veterinary Clinics (Dominant) vs. Farmers (Emerging)

Veterinary clinics serve as the dominant force in the Animal Vaccines Market due to their established relationships with pet owners and a broad spectrum of services. They provide essential vaccinations that help in the preventive healthcare of companion animals, ensuring their longevity and well-being. In contrast, farmers represent an emerging sector that is gaining traction as livestock vaccination becomes increasingly prioritized for agricultural productivity. Their emphasis on herd health management and biosecurity measures connects them to the vaccine market. The growing awareness of zoonotic diseases and the economic implications of livestock health are propelling farmers to seek effective vaccination solutions. This shift not only enriches the market landscape but also fosters collaborative efforts between veterinary clinics and farmers to enhance animal welfare across the board.

Get more detailed insights about Animal Vaccine Market Research Report - Global Forecast till 2035

Regional Insights

North America : Market Leader in Animal Vaccines

North America continues to lead The Animal Vaccines, holding a significant share of 5.76 in 2024. The region's growth is driven by increasing pet ownership, rising livestock production, and stringent regulations promoting animal health. The demand for innovative vaccines is further fueled by advancements in biotechnology and a growing awareness of zoonotic diseases. Regulatory bodies are actively supporting vaccine development, ensuring safety and efficacy, which enhances market growth. The competitive landscape in North America is robust, featuring key players such as Zoetis, Merck Animal Health, and Elanco Animal Health. The U.S. is the largest market, driven by high investments in R&D and a strong veterinary infrastructure. Canada also contributes significantly, focusing on sustainable animal farming practices. The presence of established companies and a growing number of startups in the biotech sector are expected to further enhance market dynamics.

Europe : Emerging Market with Growth Potential

Europe's animal vaccines market is valued at 3.45, reflecting a growing demand for innovative solutions in animal health. The region is witnessing increased investments in R&D, driven by a rising awareness of animal welfare and food safety. Regulatory frameworks, such as the European Medicines Agency's guidelines, are fostering innovation while ensuring compliance. The focus on sustainable agriculture and the reduction of antibiotic use are also key growth drivers in this market. Leading countries in Europe include Germany, France, and the UK, where major players like Boehringer Ingelheim and Virbac are prominent. The competitive landscape is characterized by a mix of established companies and emerging biotech firms. The European market is also seeing collaborations between public and private sectors to enhance vaccine development, ensuring a steady supply of effective vaccines to meet the growing demand.

Asia-Pacific : Rapidly Growing Animal Health Sector

The Asia-Pacific region is rapidly emerging as a significant player in the animal vaccines market, with a market size of 2.56. The growth is driven by increasing livestock production, rising pet ownership, and a growing awareness of animal health. Governments are implementing supportive regulations to enhance animal welfare, which is further propelling the demand for vaccines. The region is also witnessing advancements in veterinary healthcare, contributing to market expansion. Countries like China, India, and Australia are leading the market, with key players such as Zoetis and Merck Animal Health establishing a strong presence. The competitive landscape is evolving, with local companies also gaining traction. The increasing collaboration between governments and private sectors is expected to enhance vaccine accessibility and affordability, further driving market growth.

Middle East and Africa : Untapped Market with Growth Opportunities

The Middle East and Africa region, with a market size of 0.75, presents untapped opportunities in the animal vaccines market. The growth is driven by increasing livestock farming and a rising awareness of animal health issues. Governments are beginning to implement regulations to improve animal welfare, which is expected to boost vaccine demand. The region's diverse agricultural practices also create a unique landscape for vaccine development tailored to local needs. Leading countries in this region include South Africa and the UAE, where there is a growing focus on veterinary healthcare. The competitive landscape is characterized by a mix of local and international players, with companies like Ceva Santé Animale and Virbac making significant inroads. The increasing investment in veterinary services and infrastructure is anticipated to enhance market dynamics and accessibility to vaccines.

Key Players and Competitive Insights

The Animal Vaccines Market is characterized by a dynamic competitive landscape, driven by increasing demand for livestock health and the rising prevalence of zoonotic diseases. Key players such as Zoetis (US), Merck Animal Health (US), and Boehringer Ingelheim (DE) are at the forefront, each adopting distinct strategies to enhance their market positioning. Zoetis (US) focuses on innovation through extensive R&D investments, aiming to develop next-generation vaccines that address emerging health challenges in animals. Meanwhile, Merck Animal Health (US) emphasizes strategic partnerships and collaborations to expand its product portfolio and enhance distribution networks, thereby increasing its market reach. Boehringer Ingelheim (DE) appears to prioritize sustainability and digital transformation, integrating advanced technologies into its operations to improve efficiency and product efficacy.The competitive structure of the market is moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing. The collective influence of these major companies shapes the market dynamics, as they leverage their strengths to navigate challenges and capitalize on growth opportunities.
In November Zoetis (US) announced the launch of a novel vaccine targeting a prevalent viral disease in cattle, which is expected to significantly enhance herd immunity and reduce mortality rates. This strategic move underscores Zoetis's commitment to innovation and its proactive approach to addressing critical health issues in livestock, potentially solidifying its leadership position in the market.
In October Merck Animal Health (US) entered into a strategic alliance with a leading biotechnology firm to co-develop a new vaccine platform utilizing mRNA technology. This collaboration is likely to accelerate the development of vaccines that are more effective and quicker to produce, reflecting a shift towards cutting-edge solutions in animal health. Such partnerships may enhance Merck's competitive edge by diversifying its product offerings and improving its responsiveness to market demands.
In September Boehringer Ingelheim (DE) unveiled a comprehensive digital health platform designed to monitor animal health and vaccination status in real-time. This initiative not only demonstrates the company's commitment to digitalization but also positions it as a leader in integrating technology into veterinary practices. The platform is expected to facilitate better decision-making for veterinarians and farmers, thereby improving overall animal health outcomes.
As of December current trends in the Animal Vaccines Market indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in vaccine development and distribution. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise to drive innovation. The market appears to be shifting from price-based competition towards a focus on technological advancements and supply chain reliability. This evolution suggests that future competitive differentiation will hinge on the ability to innovate and adapt to changing consumer and regulatory demands.

Key Companies in the Animal Vaccines Market include

Industry Developments

Notably, in March 2023, Merial announced the launch of a new vaccine specifically designed for poultry, targeting recent outbreaks of avian influenza, which has significantly impacted livestock globally.

Additionally, in May 2023, Elanco Animal Health expanded its portfolio with the acquisition of a small biotech firm specializing in canine vaccines, aiming to enhance its offerings in the companion animal sector.

Other companies, including IDT Biologika and Virbac, are focusing on Research and Development for new vaccines to mitigate diseases in livestock, responding to an increasing demand for animal health solutions.

Furthermore, the market efficiency has been bolstered by a spike in investments from private equity in recent years, leading to enhanced production capabilities and innovative product offerings.

Despite challenges posed by regulatory hurdles and supply chain disruptions, the robust growth trajectory of this market indicates strong future potential, driven by increasing awareness of animal health and welfare globally.

Future Outlook

Animal Vaccines Market Future Outlook

The Animal Vaccines Market is projected to grow at a 7.62% CAGR from 2025 to 2035, driven by increasing pet ownership, livestock health awareness, and advancements in vaccine technology.

New opportunities lie in:

  • <p>Development of personalized vaccines for companion animals Expansion of telemedicine platforms for remote vaccination services Investment in biopharmaceuticals for innovative vaccine formulations</p>

By 2035, the Animal Vaccines Market is expected to achieve substantial growth and innovation.

Market Segmentation

Animal Vaccines Market End User Outlook

  • Veterinary Clinics
  • Animal Hospitals
  • Research Institutions
  • Farmers

Animal Vaccines Market Technology Outlook

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • DNA Vaccines

Animal Vaccines Market Animal Type Outlook

  • Livestock
  • Companion Animals
  • Aquatic Animals
  • Wildlife

Animal Vaccines Market Application Outlook

  • Preventive Vaccination
  • Therapeutic Vaccination
  • Emergency Vaccination

Animal Vaccines Market Route of Administration Outlook

  • Intramuscular
  • Subcutaneous
  • Oral
  • Intradermal

Report Scope

MARKET SIZE 2024 11.52 (USD Billion)
MARKET SIZE 2025 12.39 (USD Billion)
MARKET SIZE 2035 25.83 (USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 7.62% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Zoetis (US), Merck Animal Health (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Virbac (FR), Ceva Santé Animale (FR), Heska Corporation (US), Vetoquinol (FR), Phibro Animal Health (US)
Segments Covered Application, Animal Type, Route of Administration, Technology, End User
Key Market Opportunities Advancements in biotechnology enhance efficacy and safety of vaccines in the Animal Vaccines Market.
Key Market Dynamics Rising demand for innovative animal vaccines drives competitive forces and regulatory adaptations in the market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Animal Vaccines Market as of 2024?

<p>The Animal Vaccines Market was valued at 11.52 USD Billion in 2024.</p>

What is the projected market size for the Animal Vaccines Market by 2035?

<p>The market is projected to reach 25.83 USD Billion by 2035.</p>

What is the expected CAGR for the Animal Vaccines Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Animal Vaccines Market during 2025 - 2035 is 7.62%.</p>

Which companies are considered key players in the Animal Vaccines Market?

<p>Key players include Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco Animal Health, and Virbac.</p>

How does the market segment for Preventive Vaccination perform in terms of valuation?

<p>The Preventive Vaccination segment is projected to grow from 4.5 USD Billion to 10.2 USD Billion.</p>

What is the valuation range for the Therapeutic Vaccination segment?

<p>The Therapeutic Vaccination segment ranges from 3.0 USD Billion to 7.0 USD Billion.</p>

What are the projected values for the Livestock segment by 2035?

<p>The Livestock segment is expected to grow from 5.0 USD Billion to 11.5 USD Billion.</p>

What is the expected growth for the Companion Animals segment in the Animal Vaccines Market?

<p>The Companion Animals segment is projected to increase from 3.0 USD Billion to 7.0 USD Billion.</p>

Which route of administration shows the highest projected growth?

<p>The Intramuscular route of administration is expected to grow from 3.0 USD Billion to 7.0 USD Billion.</p>

What is the projected valuation for Inactivated Vaccines by 2035?

<p>Inactivated Vaccines are projected to grow from 3.45 USD Billion to 7.8 USD Billion by 2035.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Application (USD Billion)
    2. | | 4.1.1 Preventive Vaccination
    3. | | 4.1.2 Therapeutic Vaccination
    4. | | 4.1.3 Emergency Vaccination
    5. | | 4.1.4 Research and Development
    6. | 4.2 Healthcare, BY Animal Type (USD Billion)
    7. | | 4.2.1 Livestock
    8. | | 4.2.2 Companion Animals
    9. | | 4.2.3 Aquatic Animals
    10. | | 4.2.4 Wildlife
    11. | 4.3 Healthcare, BY Route of Administration (USD Billion)
    12. | | 4.3.1 Intramuscular
    13. | | 4.3.2 Subcutaneous
    14. | | 4.3.3 Oral
    15. | | 4.3.4 Intradermal
    16. | 4.4 Healthcare, BY Technology (USD Billion)
    17. | | 4.4.1 Inactivated Vaccines
    18. | | 4.4.2 Live Attenuated Vaccines
    19. | | 4.4.3 Recombinant Vaccines
    20. | | 4.4.4 DNA Vaccines
    21. | 4.5 Healthcare, BY Region (USD Billion)
    22. | | 4.5.1 North America
    23. | | | 4.5.1.1 US
    24. | | | 4.5.1.2 Canada
    25. | | 4.5.2 Europe
    26. | | | 4.5.2.1 Germany
    27. | | | 4.5.2.2 UK
    28. | | | 4.5.2.3 France
    29. | | | 4.5.2.4 Russia
    30. | | | 4.5.2.5 Italy
    31. | | | 4.5.2.6 Spain
    32. | | | 4.5.2.7 Rest of Europe
    33. | | 4.5.3 APAC
    34. | | | 4.5.3.1 China
    35. | | | 4.5.3.2 India
    36. | | | 4.5.3.3 Japan
    37. | | | 4.5.3.4 South Korea
    38. | | | 4.5.3.5 Malaysia
    39. | | | 4.5.3.6 Thailand
    40. | | | 4.5.3.7 Indonesia
    41. | | | 4.5.3.8 Rest of APAC
    42. | | 4.5.4 South America
    43. | | | 4.5.4.1 Brazil
    44. | | | 4.5.4.2 Mexico
    45. | | | 4.5.4.3 Argentina
    46. | | | 4.5.4.4 Rest of South America
    47. | | 4.5.5 MEA
    48. | | | 4.5.5.1 GCC Countries
    49. | | | 4.5.5.2 South Africa
    50. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Zoetis (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Merck Animal Health (US)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Boehringer Ingelheim (DE)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Elanco Animal Health (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Virbac (FR)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Ceva Santé Animale (FR)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Heska Corporation (US)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Vetoquinol (FR)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | 5.3 Appendix
    65. | | 5.3.1 References
    66. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY APPLICATION
    4. | 6.4 US MARKET ANALYSIS BY ANIMAL TYPE
    5. | 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. | 6.6 US MARKET ANALYSIS BY TECHNOLOGY
    7. | 6.7 CANADA MARKET ANALYSIS BY APPLICATION
    8. | 6.8 CANADA MARKET ANALYSIS BY ANIMAL TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    10. | 6.10 CANADA MARKET ANALYSIS BY TECHNOLOGY
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
    13. | 6.13 GERMANY MARKET ANALYSIS BY ANIMAL TYPE
    14. | 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    15. | 6.15 GERMANY MARKET ANALYSIS BY TECHNOLOGY
    16. | 6.16 UK MARKET ANALYSIS BY APPLICATION
    17. | 6.17 UK MARKET ANALYSIS BY ANIMAL TYPE
    18. | 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    19. | 6.19 UK MARKET ANALYSIS BY TECHNOLOGY
    20. | 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
    21. | 6.21 FRANCE MARKET ANALYSIS BY ANIMAL TYPE
    22. | 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    23. | 6.23 FRANCE MARKET ANALYSIS BY TECHNOLOGY
    24. | 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
    25. | 6.25 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE
    26. | 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    27. | 6.27 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
    28. | 6.28 ITALY MARKET ANALYSIS BY APPLICATION
    29. | 6.29 ITALY MARKET ANALYSIS BY ANIMAL TYPE
    30. | 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    31. | 6.31 ITALY MARKET ANALYSIS BY TECHNOLOGY
    32. | 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
    33. | 6.33 SPAIN MARKET ANALYSIS BY ANIMAL TYPE
    34. | 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    35. | 6.35 SPAIN MARKET ANALYSIS BY TECHNOLOGY
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY APPLICATION
    42. | 6.42 CHINA MARKET ANALYSIS BY ANIMAL TYPE
    43. | 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    44. | 6.44 CHINA MARKET ANALYSIS BY TECHNOLOGY
    45. | 6.45 INDIA MARKET ANALYSIS BY APPLICATION
    46. | 6.46 INDIA MARKET ANALYSIS BY ANIMAL TYPE
    47. | 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    48. | 6.48 INDIA MARKET ANALYSIS BY TECHNOLOGY
    49. | 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
    50. | 6.50 JAPAN MARKET ANALYSIS BY ANIMAL TYPE
    51. | 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    52. | 6.52 JAPAN MARKET ANALYSIS BY TECHNOLOGY
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
    61. | 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
    62. | 6.62 THAILAND MARKET ANALYSIS BY ANIMAL TYPE
    63. | 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    64. | 6.64 THAILAND MARKET ANALYSIS BY TECHNOLOGY
    65. | 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
    66. | 6.66 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE
    67. | 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    68. | 6.68 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
    75. | 6.75 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE
    76. | 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    77. | 6.77 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
    78. | 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
    79. | 6.79 MEXICO MARKET ANALYSIS BY ANIMAL TYPE
    80. | 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    81. | 6.81 MEXICO MARKET ANALYSIS BY TECHNOLOGY
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY TECHNOLOGY, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Preventive Vaccination
  • Therapeutic Vaccination
  • Emergency Vaccination
  • Research and Development

Healthcare By Animal Type (USD Billion, 2025-2035)

  • Livestock
  • Companion Animals
  • Aquatic Animals
  • Wildlife

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Intramuscular
  • Subcutaneous
  • Oral
  • Intradermal

Healthcare By Technology (USD Billion, 2025-2035)

  • Inactivated Vaccines
  • Live Attenuated Vaccines
  • Recombinant Vaccines
  • DNA Vaccines
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓